Prostate Cancer, Androgen Deprivation Therapy, Obesity, the Metabolic Syndrome, Type 2 Diabetes, and Cardiovascular Disease

2012 ◽  
Vol 35 (5) ◽  
pp. 504-509 ◽  
Author(s):  
Andrew Collier ◽  
Sujoy Ghosh ◽  
Brian McGlynn ◽  
Graham Hollins
Keyword(s):  
Prostate Cancer ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Syndrome Type ◽  
The Metabolic Syndrome

The Metabolic Syndrome and its Components in Patients with Prostate Cancer on Androgen Deprivation Therapy

2015 ◽  
Vol 193 (6) ◽  
pp. 1963-1969 ◽  
Author(s):  
Juan Morote ◽  
Antonio Gómez-Caamaño ◽  
José L. Alvarez-Ossorio ◽  
Daniel Pesqueira ◽  
Angel Tabernero ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metabolic Syndrome ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
The Metabolic Syndrome

scholarly journals Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy

2016 ◽  
Vol 10 (9-10) ◽  
pp. 300 ◽  
Author(s):  
Mohammadali Mohammadzadeh Rezaei ◽  
Mohammadhadi Mohammadzadeh Rezaei ◽  
Alireza Ghoreifi ◽  
Behzad Feyzzadeh Kerigh
Keyword(s):  
Prostate Cancer ◽  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Safe Alternative ◽  
Metabolic Complications ◽  
The Metabolic Syndrome ◽  
Increased Risk ◽  
Blood Pressures

<p><strong>Introduction:</strong> The presence of metabolic syndrome in men with prostate cancer (PCa) undergoing androgen-deprivation therapy (ADT), especially intermittent type, has not been completely evaluated. The aim of this study is to evaluate metabolic syndrome in men with PCa undergoing intermittent ADT.</p><p><strong>Methods:</strong> In this longitudinal study, we studied the prevalence of metabolic syndrome and its components in 190 patients who were undergoing intermittent ADT. The metabolic syndrome was defined according to the Adult Treatment Panel III criteria. All metabolic parameters, including lipid profile, blood glucose, blood pressures, and waist circumferences of the patients were measured six and 12 months after treatment.</p><p><strong>Results:</strong> Mean age of the patients was 67.5 ± 6.74 years. The incidence of metabolic syndrome after six and 12 months was 6.8% and 14.7%, respectively. Analysis of various components of the metabolic syndrome revealed that patients had significantly higher overall prevalence of hyperglycemia, abdominal obesity, and hypertriglyceridemia in their six- and 12-month followups, but blood pressure has not been changed in the same period except for diastolic blood pressure after six months.</p><p><strong>Conclusions:</strong> Although there was an increased risk of metabolic syndrome in patients receiving intermittent ADT, it was lower than other studies that treated the same patients with continuous ADT. Also it seems that intermittent ADT has less metabolic complications than continuous ADT and could be used as a safe alternative in patients with advanced and metastatic PCa.</p>

Sign in / Sign up

Export Citation Format

Share Document